We propose to assess the impact of sex-steroid hormones and prostate cancer (PCa) progression in the context of the recently identified TMPRSS2:ERG translocation, a novel gene fusion of the 5'-untranslated region of the androgen-regulated TMPRSS2 promoter and the ETS transcription factor family member. The TMPRSS2:ERG translocation is a common molecular event in PCa, and emerging data (including our own) suggest men with tumors with the translocation tend to have a worse cancer prognosis. The regulation of TMPRSS2 by androgens and possibly estrogens is intriguing and illuminates a potential mechanism whereby sex hormones could drive tumor growth and proliferation leading to worse cancer survival. We have identified 1,500 men diagnosed with incident PCa in the Physicians'Health Study and Health Professionals Follow-up Study during 1982 to 2006, and will continue prospective follow-up through 2012 for outcomes (175 will have developed metastatic or fatal disease). We have assembled a repository of archival tumor tissue, and will characterize the TMPRSS2:ERG tumor status using fluorescent in situ hybridization. We will explore the role of the TMPRSS2:ERG fusion on PCa progression. Moreover, we will examine whether circulating levels of sex hormones or variation in genes involved in sex hormone signaling or metabolism interact with the fusion to affect progression;we hypothesize that men with fusion positive tumors have a worse prognosis if they are exposed to high sex hormone levels. We will evaluate whether obesity, with its known regulation of the hormonal milieu causing higher levels of estrogen and reduced testosterone, is associated with PCa progression by interacting with the TMPRSS2:ERG fusion. At the tumor level, we will examine the relation between fusion status, alone and in concert with hormones, and extent of tumor angiogenesis, cellular proliferation and apoptosis. Finally, we will evaluate whether men with fusion positive tumors have a more favorable response to androgen deprivation therapy compared to those without the TMPRSS2:ERG fusion. Based on the incidence of PCa in the United States and frequency of the fusion, more than 100,000 men diagnosed each year have a fusion positive PCa. If these tumors are indeed more aggressive, this number reflects a considerable burden of men at risk of progression. As such, an understanding of the TMPRSS2:ERG fusion on PCa survival in light of the hormonal milieu could have significant public health impact, and illuminate opportunities for primary and secondary prevention or improved patient selection for specific therapeutic intervention.
PCa is a significant public health burden with respect to morbidity and mortality among men in the Western World. The recent identification of a common novel translocation in PCa, the TMPRSS2:ERG fusion, may help explain the heterogeneity of this disease, although there is still limited research in this area. Our study seeks to explore the role of the TMPRSS2:ERG translocation in PCa progression within two large, community-based cohorts of men with PCa, and to understand whether genetic factors, hormones or lifestyle factors interact with the fusion to impact cancer mortality.
|Penney, Kathryn L; Sinnott, Jennifer A; Tyekucheva, Svitlana et al. (2015) Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev 24:255-60|
|Gershman, Boris; Shui, Irene M; Stampfer, Meir et al. (2014) Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol 65:683-9|
|Zu, Ke; Mucci, Lorelei; Rosner, Bernard A et al. (2014) Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst 106:djt430|
|Zu, Ke; Martin, Neil E; Fiorentino, Michelangelo et al. (2013) Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 22:1984-93|
|Hendrickson, Whitney K; Flavin, Richard; Kasperzyk, Julie L et al. (2011) Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 29:2378-85|
|Ding, Zhihu; Wu, Chang-Jiun; Chu, Gerald C et al. (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470:269-73|
|Fiorentino, Michelangelo; Capizzi, Elisa; Loda, Massimo (2010) Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am 37:131-41, Table of Contents|